Subtype
Exocrine Pancreas Carcinoma
CI-CAN-00005225Explore in graph →
358 active trials5 approved drugs26 evidence items
- NCIt
- C3850
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005225Explore in graph →
Clinical trials
919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (136)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01233375 | Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | completed | Phase 2 | 19 | Clovis Oncology, Inc.INDUSTRY | 1 | Mar 11, 2019 | clinicaltrials |
| NCT02440958 | Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | completed | Phase 2 | 50 | Yonsei UniversityOTHER | 0 | Feb 18, 2019 | clinicaltrials |
| NCT03054987 | Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction | completed | N/A | 67 | AdventHealthOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03152487 | Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis | completed | N/A | 28 | AdventHealthOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT02005419 | Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 300 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02023021 | Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 80 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02847000 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | completed | Early Phase 1 | 13 | Yogen SaunthararajahOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT01839981 | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 10 | Wake Forest University Health SciencesOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT01770132 | Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 12 | John DeWittOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT02045589 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 8 | Theriva Biologics SLINDUSTRY | 1 | Oct 1, 2018 | clinicaltrials |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 1 | 11 | Oncolytics BiotechINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01456585 | Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT02028377 | Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma | completed | N/A | 25 | Washington University School of MedicineOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT00600002 | Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma | completed | Phase 1 | 30 | Edward NelsonOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT02657330 | Study of SBP-101 in Pancreatic Cancer | completed | Phase 1 | 29 | Panbela Therapeutics, Inc.INDUSTRY | 2 | Apr 20, 2018 | clinicaltrials |
| NCT01342224 | Immunochemoradiotherapy in Patients With Pancreatic Cancer | completed | Phase 1 | 11 | Providence Health & ServicesOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT03032913 | Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC(PANC-CTC) | completed | — | 52 | University Hospital, BordeauxOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02680990 | Resilience and Exercise in Advanced Cancer Treatment(REACT) | completed | N/A | 14 | Milton S. Hershey Medical CenterOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | completed | Phase 2 | 8 | Translational Oncology Research InternationalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00383760 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01897415 | Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer | completed | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01783171 | Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 2 | Aug 22, 2017 | clinicaltrials |
| NCT00288093 | 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01764477 | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma | completed | Phase 1 | 20 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00609336 | Perioperative Therapy for Resectable Pancreatic Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01016483 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 141 | EMD SeronoINDUSTRY | 2 | Jul 13, 2017 | clinicaltrials |
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02174887 | Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer(MOAnab1) | completed | Phase 1 | 19 | Institut Paoli-CalmettesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01753479 | Spectroscopy From Duodenum | completed | N/A | 445 | Olympus CorporationINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT01369420 | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 10 | Angiodynamics, Inc.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer(ONTRAC) | completed | Phase 3 | 160 | Traws Pharma, Inc.INDUSTRY | 5 | Aug 4, 2016 | clinicaltrials |
| NCT01274455 | Gene Therapy of Pancreatic Ductal Adenocarcinoma(TherGAP) | completed | Phase 1 | 22 | University Hospital, ToulouseOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01658943 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy(S1115) | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00375310 | Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 | 27 | Indiana UniversityOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | completed | Phase 1 | 26 | David BartlettOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT01674556 | Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer | completed | Phase 1 | 25 | Haukeland University HospitalOTHER | 1 | Sep 24, 2015 | clinicaltrials |
| NCT00474812 | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00588367 | CT Pancreas Perfusion | completed | — | 30 | Mayo ClinicOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 34 | Oncolytics BiotechINDUSTRY | 1 | Apr 10, 2015 | clinicaltrials |
| NCT01834170 | EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 1 | 12 | University of TehranOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01232829 | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00577889 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00331682 | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00091026 | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01124786 | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | completed | Phase 2 | 367 | Clovis Oncology, Inc.INDUSTRY | 15 | Apr 17, 2014 | clinicaltrials |
| NCT00203892 | Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma | completed | Phase 1 / Phase 2 | 23 | University of ChicagoOTHER | 1 | Apr 16, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Mar 11, 2019source: clinicaltrials